

Special Issue

Surgical Approach to Primary Lung Cancer and Metastatic Solid Tumors Involving the Lung

Message from the Guest Editors

Lung cancer is the second most frequent tumor and the leading cause of cancer death among both women and men, causing almost 25% of all cancer deaths. On the other side, the lung is the second most frequent target of metastases that form solid tumors, and pulmonary metastasectomy represents the most common surgical procedure in thoracic surgery. Lung metastasectomy is an effective therapeutic alternative in selected patients, depending on primary tumor's biology, disease-free interval, number and site of the nodule to be excised, planned extension of lung resection as well as available alternative therapeutic options. Another surgical option widely debated involves the field of synchronous or metachronous lung cancers paving the way to a personalized therapeutic strategy in particular in the era of immune-therapy and precision medicine. In this Special Issue, we would like to analyze the most significant advancements in the therapy of both primary and secondary lung tumors. We look forward to receiving your valuable participations.

Dr. Francesco Petrella

Guest Editors

Dr. Diego Luigi Cortinovis

Dr. Francesco Petrella

Dr. Francesca Colonese

Deadline for manuscript submissions

closed (15 September 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/191636

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)